Over the past decade, the emergence of effective immunotherapies has revolutionized the
clinical management of many types of cancers. However, long-term durable tumour control …

Cancer development is an evolutionary process. A key selection pressure is exerted by
therapy, one of the few players in cancer evolution that can be controlled. As such, an …

Progress in sequencing technologies and clinical experiments has revolutionized
immunotherapy on solid and hematologic malignancies. However, the benefits of …

The human leukocyte antigen (HLA) system is a major factor controlling cancer
immunosurveillance and response to immunotherapy, yet its status in pediatric cancers …

Reconstructing diploid sequences of human leukocyte antigen (HLA) genes, ie, full-
resolution HLA typing, from sequencing data is challenging. The high homogeneity across …

To enable interrogation of tumor HLA LOH as a clinical diagnostic for precision oncology, we
developed and validated an assay that detects HLA LOH within the context of an FDA …

Simple Summary Cancer immune evasion poses a significant challenge in developing
effective cancer treatments. The interplay between the immune system and tumors …

Lung cancer is one of the most prevalent malignancies worldwide, contributing to over a
million cancer-related deaths annually. Despite extensive research investigating the genetic …

Objectives/Hypothesis Cancer cells evade recognition by the immune system to survive.
Head and neck squamous cell carcinoma (HNSCC) is characterized by high levels of …

Neoantigens have emerged as promising targets for cutting-edge immunotherapies, such as
cancer vaccines and adoptive cell therapy. These neoantigens are unique to tumors and …